-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on United Therapeutics, Raises Price Target to $725

Benzinga·10/19/2026 14:29:02
Leerink Partners analyst Roanna Ruiz maintains United Therapeutics (NASDAQ:UTHR) with a Outperform and raises the price target from $685 to $725.